Longer Term Results from a Phase I/II Study of EP-guided Noninvasive Cardiac Radioablation for Treatment of Ventricular Tachycardia (ENCORE-VT)

A prospective phase I/II trial of noninvasive cardiac radioablation in high risk patients with treatment-refractory episodes of ventricular arrhythmias demonstrated acceptable primary endpoint 90-day and 6-month safety profile with 11% serious adverse event (SAE) rate, 94% reduction in ventricular tachycardia (VT) episodes, and 89% 6-month overall survival (OS). Longer-term safety and efficacy of this technique is reported.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Source Type: research